Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

CRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow. In 2025, the company incurred a loss of more than $580 million. Its cash position, however, remains strong.

Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...